Suvretta Capital Management LLC Has $4.22 Million Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Suvretta Capital Management LLC lowered its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 53.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,182,791 shares of the company’s stock after selling 1,358,255 shares during the period. Suvretta Capital Management LLC’s holdings in Fulcrum Therapeutics were worth $4,223,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Fulcrum Therapeutics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock valued at $23,965,000 after acquiring an additional 18,681 shares in the last quarter. Jane Street Group LLC raised its position in shares of Fulcrum Therapeutics by 54.3% in the first quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock valued at $5,051,000 after purchasing an additional 188,212 shares during the period. SG Americas Securities LLC lifted its stake in shares of Fulcrum Therapeutics by 113.8% in the second quarter. SG Americas Securities LLC now owns 26,093 shares of the company’s stock worth $162,000 after buying an additional 13,887 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth $3,084,000. Finally, Bank of New York Mellon Corp acquired a new position in Fulcrum Therapeutics in the 2nd quarter valued at $1,158,000. Institutional investors own 89.83% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Leerink Partnrs cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Bank of America downgraded Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $10.00 to $2.00 in a research note on Thursday, September 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald cut Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Finally, Leerink Partners restated a “market perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Trading Up 11.3 %

FULC opened at $3.95 on Friday. The firm’s fifty day moving average price is $3.43 and its two-hundred day moving average price is $6.22. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $13.70.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.